NCT05995405Phase 3Active not recruiting

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Study sponsor: Grace Therapeutics Inc. · GRCE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12Estimated
Enrollment · participants100Estimated
Source updated2024-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview